Transcatheter tricuspid edge-to-edge repair (T-TEER) offers a promising, minimally invasive alternative to surgical tricuspid valve repair or replacement for patients with severe tricuspid regurgitation (TR). A new systematic review and meta-analysis, presented at the European Society of Cardiology (ESC) Congress 2025, evaluated outcomes in 1,612 patients across three retrospective observational studies.

The analysis found that short-term mortality was similar between T-TEER and surgical intervention (odds ratio 0.36; 95% confidence interval 0.13–1.04). Importantly, T-TEER was associated with a lower risk of acute kidney injury (OR 0.31; 95% CI 0.23–0.43) and reduced need for permanent pacemaker implantation (OR 0.19; 95% CI 0.10–0.35). Rates of stroke and bleeding complications were comparable between the two approaches.

These results suggest that T-TEER provides a safe and effective less-invasive treatment option, particularly for patients considered high risk for surgery. While current evidence supports favorable short-term outcomes, further research is needed to confirm long-term efficacy and integrate T-TEER into routine clinical practice and guideline recommendations.